# EmpowHER-303 (NCT06435429)

> A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06435429
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Jazz Pharmaceuticals
- Conditions: Metastatic HER2-positive Breast Cancer
- Interventions: Zanidatamab; Trastuzumab; Eribulin; Vinorelbine; Gemcitabine; Capecitabine
- Enrollment: 550
- Primary outcome: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on EmpowHER-303 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=empowher-303-nct06435429

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06435429", "email": "<work email>"}; the inbox owner confirms by the emailed link.